Primo N Lara Jr
Overview
Explore the profile of Primo N Lara Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
205
Citations
6380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lara M, Riess J, Kaleka G, Borowsky A, McPherson J, Godoy L, et al.
Clin Lung Cancer
. 2025 Feb;
PMID: 39894709
No abstract available.
2.
Swami U, Jo Y, Narang A, Plets M, Hage Chehade C, Gebrael G, et al.
Eur Urol Oncol
. 2024 Nov;
PMID: 39521639
Although obesity has been associated with better overall survival (OS) among patients with metastatic castration-resistant prostate cancer, its association with OS has not been extensively explored in metastatic hormone-sensitive prostate...
3.
Ryan C, Tangen C, Lara Jr P
Lancet
. 2024 Nov;
404(10465):1810.
PMID: 39521508
No abstract available.
4.
Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski J, et al.
JAMA Netw Open
. 2024 Oct;
7(10):e2437871.
PMID: 39374015
Importance: In metastatic hormone-sensitive prostate cancer (mHSPC), new first-line combination therapies have enhanced overall survival (OS), but clinical outcomes for individual patients vary greatly and are difficult to predict. Peripheral...
5.
Barata P, Tangen C, Plets M, Thompson Jr I, Narayan V, George D, et al.
J Clin Oncol
. 2024 Sep;
42(33):3911-3916.
PMID: 39255440
JCO Mesenchymal-epithelial transition (MET) signaling pathway plays a role in the pathogenesis of selected patients with papillary renal cell carcinoma (PRCC). In the phase II PAPMET trial (ClinicalTrials.gov identifier: NCT02761057),...
6.
Gulati S, Tangen C, Ryan C, Vaishampayan U, Shuch B, Barata P, et al.
JAMA Netw Open
. 2024 Aug;
7(8):e2425288.
PMID: 39106067
Importance: Clinical trial data on adjuvant therapy in patients with non-clear cell renal cell carcinoma (RCC) are scant. Objective: To evaluate the effect of adjuvant everolimus after nephrectomy on recurrence-free...
7.
Lara Jr P, Villanueva L, Ibanez C, Erman M, Lee J, Heinrich D, et al.
BMC Cancer
. 2024 Jul;
23(Suppl 1):1253.
PMID: 39054430
Background: Immunotherapy-based combinations have emerged as standard therapies for patients with metastatic renal cell carcinoma (mRCC). Pembrolizumab, a PD-1 inhibitor, combined with epacadostat, an indoleamine 2,3-deoxygenase 1 selective inhibitor, demonstrated...
8.
Tripathi A, Tangen C, Plets M, Li X, Tretiakova M, Humphrey P, et al.
BJU Int
. 2024 Jul;
134(4):596-601.
PMID: 39014969
Objective: To evaluate the clinical significance of subtyping (type 1 vs 2) of papillary renal cell carcinoma (PRCC) in patients treated with targeted therapy, as well as the concordance, sensitivity...
9.
Gebrael G, Jo Y, Swami U, Plets M, Hage Chehade C, Narang A, et al.
JAMA Netw Open
. 2024 Jul;
7(7):e2419966.
PMID: 38980676
Importance: The presence of bone pain is significantly associated with worse overall survival (OS) in patients with castration-resistant prostate cancer. However, there are few data regarding bone pain and survival...
10.
Lara Jr P, Tangen C, Heath E, Gulati S, Stein M, Meng M, et al.
Eur Urol
. 2024 May;
86(3):258-264.
PMID: 38811313
Background And Objective: EVEREST is a phase 3 trial in patients with renal cell cancer (RCC) at intermediate-high or very high risk of recurrence after nephrectomy who were randomized to...